QCG
CRMD icon

Quadrant Capital Group’s CorMedix CRMD Stock Holding History

Quadrant Capital Group’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.24K Buy
+625
New +$4.62K ﹤0.01% 2391

Other funds holding CRMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $3.39B AUM 105.5% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Quadrant Capital Group's CRMD Position: Q1 2026 in Review

Quadrant Capital Group opened a new position in CorMedix (CRMD) in Q1 2026: 625 shares worth $4.24K. The stake represents ﹤0.01% of the portfolio and ranks #2391 among its holdings.

187 funds tracked by Wall St. Rank hold CRMD as of Q1 2026.

  • Quadrant Capital Group held 625 shares of CorMedix worth $4.24K as of Q1 2026.
  • CorMedix was a new Quadrant Capital Group position in Q1 2026.
  • CorMedix made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2391 holding.
  • 187 funds tracked by Wall St. Rank held CorMedix as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.